Who
Maria Fardis
Director
Company insider
Files Form 4 as: Director, Obsidian Therapeutics; Director, CRISPR Therapeutics AG; President and CEO, Iovance Biotherapeutics; Chief of Oncology Ops & Allian, Pharmacyclics.
In numbers
- Trades disclosed
- 76
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $2.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 7 Jan 2012
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | OBX Obsidian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,653 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | OBX Obsidian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,653 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 30 May 2024filed 31 May 2024 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 4 Jan 2021filed 6 Jan 2021 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 Jun 2020filed 2 Jun 2020 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $63K1,894 at $33.12 | filing |
| 1 May 2020filed 4 May 2020 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $61K1,894 at $32.00 | filing |
| 1 Apr 2020filed 3 Apr 2020 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $42K1,494 at $27.94 | filing |
| 2 Mar 2020filed 4 Mar 2020 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $48K1,321 at $35.99 | filing |
| 3 Feb 2020filed 5 Feb 2020 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $29K1,302 at $22.54 | filing |
| 3 Jan 2020filed 7 Jan 2020 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 2 Jan 2020filed 6 Jan 2020 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $42K1,562 at $26.68 | filing |
| 2 Dec 2019filed 4 Dec 2019 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $43K1,894 at $22.66 | filing |
| 1 Nov 2019filed 4 Dec 2019 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $42K1,894 at $21.97 | filing |
| 1 Oct 2019filed 4 Dec 2019 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $34K1,894 at $18.21 | filing |
| 3 Sep 2019filed 4 Dec 2019 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $33K1,610 at $20.27 | filing |
News
No headline names them, or the companies they trade most, lately.